Medincell Announces Participation in Leading Investor Conferences

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:

Members of Medincell’s (Paris: MEDCL) management team will participate in the following investor conferences in November and December 2024.

Truist Securities BioPharma Symposium

• Time: November 7, 2024
• Location: New York, NY (USA)

UBS Global Healthcare Conference

• Time: November 11-14, 2024
• Location: Ranch Palos Verdes, CA (USA)
• Presentation: Tuesday, November 12, 2024, at 8:00 am PST (5:00 pm Europe/Paris)

Jefferies London Healthcare Conference

• Time: November 19-21, 2024
• Location: London (UK)
• Presentation: Wednesday, November 20, 2024, at 8:30 am GMT (9:30 am Europe/Paris)

Annual Evercore ISI HealthCONx Conference

• Time: December 3-5, 2024
• Location: Coral Gables, FL (USA)
• Fireside chat: Wednesday, December 4, 2024, at 1:45 pm ET (7:45 pm Europe/Paris)

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell at [email protected].

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

UZEDY® and SteadyTeq™ are registered trademarks of Teva Pharmaceuticals.

www.medincell.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241028001063/en/

David Heuzé - Head of Corporate and Financial Communications, and ESG
[email protected] / +33 (0)6 83 25 21 86

Grace Kim - Head of US Financial Strategy and IR
[email protected] / +1 (646) 991-4023

Investors Relations France
Louis-Victor Delouvrier / Alban Dufumier
[email protected] / +33 (0)1 44 71 94 94

Media Relations
Nicolas Mérigeau
[email protected] / +33 (0)1 44 71 94 94

Source: Medincell

You May Also Be Interested In

• Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
• ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen
• Liberty Global Tech Ventures Invests in AI Inference Hardware and Software Company, Positron AI